Asset Details
Do you wish to reserve the book?
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice
Do you wish to request the book?
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice
2011
Overview
Acute promyelocytic leukemia (APL) is characterized by the t(15;17) translocation that generates the fusion protein promyelocytic leukemia-retinoic acid receptor α (PML-RARA) in nearly all cases. Multiple prior mouse models of APL constitutively express PML-RARA from a variety of non-Pml loci. Typically, all animals develop a myeloproliferative disease, followed by leukemia in a subset of animals after a long latent period. In contrast, human APL is not associated with an antecedent stage of myeloproliferation. To address this discrepancy, we have generated a system whereby PML-RARA expression is somatically acquired from the mouse Pml locus in the context of Pml haploinsufficiency. We found that physiologic PML-RARA expression was sufficient to direct a hematopoietic progenitor self-renewal program in vitro and in vivo. However, this expansion was not associated with evidence of myeloproliferation, more accurately reflecting the clinical presentation of human APL. Thus, at physiologic doses, PML-RARA primarily acts to increase hematopoietic progenitor self-renewal, expanding a population of cells that are susceptible to acquiring secondary mutations that cause progression to leukemia. This mouse model provides a platform for more accurately dissecting the early events in APL pathogenesis.
Publisher
American Society for Clinical Investigation
Subject
/ Female
/ Humans
/ Leukemia
/ Leukemia, Promyelocytic, Acute - etiology
/ Leukemia, Promyelocytic, Acute - genetics
/ Male
/ Mice
/ Myeloproliferative Disorders - etiology
/ Myeloproliferative Disorders - genetics
/ Oncogene Proteins, Fusion - genetics
/ Oncogene Proteins, Fusion - physiology
/ Proteins
